ZA200607104B - Compounds as inhibitors of hepatitis C virus NS3 Serine protease - Google Patents

Compounds as inhibitors of hepatitis C virus NS3 Serine protease

Info

Publication number
ZA200607104B
ZA200607104B ZA200607104A ZA200607104A ZA200607104B ZA 200607104 B ZA200607104 B ZA 200607104B ZA 200607104 A ZA200607104 A ZA 200607104A ZA 200607104 A ZA200607104 A ZA 200607104A ZA 200607104 B ZA200607104 B ZA 200607104B
Authority
ZA
South Africa
Prior art keywords
hepatitis
virus
inhibitors
compounds
serine protease
Prior art date
Application number
ZA200607104A
Other languages
English (en)
Inventor
Venkatraman Srikanth
Melissa L Blackman
Latha G Nair
Stephane L Bogen
Sanningrahi Mousumi
Viyyoor M Girijavallabhan
Njoroge F George
Wu Wanli
Arasappan Ashok
Kevin X Chen
Bennett Frank
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp filed Critical Schering Corp
Publication of ZA200607104B publication Critical patent/ZA200607104B/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/52—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring condensed with a ring other than six-membered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
    • C07K5/06034—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06078—Dipeptides with the first amino acid being neutral and aromatic or cycloaliphatic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Virology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyrrole Compounds (AREA)
ZA200607104A 2004-02-27 2006-08-24 Compounds as inhibitors of hepatitis C virus NS3 Serine protease ZA200607104B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US54850704P 2004-02-27 2004-02-27

Publications (1)

Publication Number Publication Date
ZA200607104B true ZA200607104B (en) 2008-09-25

Family

ID=34962171

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA200607104A ZA200607104B (en) 2004-02-27 2006-08-24 Compounds as inhibitors of hepatitis C virus NS3 Serine protease

Country Status (16)

Country Link
US (3) US7192957B2 (es)
EP (1) EP1748983A2 (es)
JP (1) JP2007525510A (es)
KR (1) KR20060127162A (es)
CN (1) CN1946691A (es)
AR (1) AR047902A1 (es)
AU (1) AU2005222055A1 (es)
BR (1) BRPI0508095A (es)
CA (1) CA2557247A1 (es)
EC (1) ECSP066795A (es)
IL (1) IL177545A0 (es)
NO (1) NO20064356L (es)
RU (1) RU2006134005A (es)
TW (1) TW200602037A (es)
WO (1) WO2005087721A2 (es)
ZA (1) ZA200607104B (es)

Families Citing this family (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7635694B2 (en) * 2004-02-27 2009-12-22 Schering Corporation Cyclobutenedione-containing compounds as inhibitors of hepatitis C virus NS3 serine protease
EP1898941A2 (en) * 2005-06-02 2008-03-19 Schering Corporation Controlled-release formulation useful for treating disorders associated with hepatitis c virus
US20060276406A1 (en) * 2005-06-02 2006-12-07 Schering Corporation Methods of treating hepatitis C virus
US20060276404A1 (en) * 2005-06-02 2006-12-07 Anima Ghosal Medicaments and methods combining a HCV protease inhibitor and an AKR competitor
US20060276407A1 (en) * 2005-06-02 2006-12-07 Schering Corporation Methods of treating hepatitis C virus
US20060275366A1 (en) * 2005-06-02 2006-12-07 Schering Corporation Controlled-release formulation
US20070237818A1 (en) * 2005-06-02 2007-10-11 Malcolm Bruce A Controlled-release formulation of HCV protease inhibitor and methods using the same
US20070021351A1 (en) * 2005-06-02 2007-01-25 Schering Corporation Liver/plasma concentration ratio for dosing hepatitis C virus protease inhibitor
AU2006252553B2 (en) * 2005-06-02 2012-03-29 Merck Sharp & Dohme Corp. Combination of HCV protease inhibitors with a surfactant
PL1891089T3 (pl) 2005-06-02 2015-05-29 Merck Sharp & Dohme Inhibitory proteazy HCV w połączeniu z pokarmem
US20060281689A1 (en) * 2005-06-02 2006-12-14 Schering Corporation Method for modulating activity of HCV protease through use of a novel HCV protease inhibitor to reduce duration of treatment period
AR055395A1 (es) 2005-08-26 2007-08-22 Vertex Pharma Compuestos inhibidores de la actividad de la serina proteasa ns3-ns4a del virus de la hepatitis c
US7816348B2 (en) 2006-02-03 2010-10-19 Boehringer Ingelheim International Gmbh Viral polymerase inhibitors
EP1998765A2 (en) * 2006-03-03 2008-12-10 Schering Corporation Pharmaceutical combinations of hcv-protease and -ires inhibitors
WO2007120595A2 (en) * 2006-04-11 2007-10-25 Novartis Ag Amines for the treatment of hcv
US20080045530A1 (en) * 2006-04-11 2008-02-21 Trixi Brandl Organic Compounds and Their Uses
NZ571826A (en) 2006-04-11 2012-01-12 Novartis Ag HCV/HIV inhibitors and their uses
AR060385A1 (es) * 2006-04-11 2008-06-11 Novartis Ag Compuestos organicos y sus usos
JP2009538327A (ja) 2006-05-23 2009-11-05 アイアールエム・リミテッド・ライアビリティ・カンパニー チャネル活性化プロテアーゼ阻害剤である化合物および組成物
MX2009000882A (es) 2006-08-17 2009-02-04 Boehringer Ingelheim Int Inhibidores de la polimerasa virica.
CA2673111A1 (en) * 2006-12-07 2008-06-19 Schering Corporation Ph sensitive matrix formulation
EA016327B1 (ru) 2007-02-09 2012-04-30 Айрм Ллк Соединения и композиции в качестве ингибиторов протеазы, активирующей каналы
FR2914920B1 (fr) 2007-04-11 2011-09-09 Clariant Specialty Fine Chem F Procede de deacetalisation d'alpha-aminoacetals.
EP2188274A4 (en) 2007-08-03 2011-05-25 Boehringer Ingelheim Int VIRAL POLYMERASE HEMMER
AR068756A1 (es) * 2007-10-10 2009-12-02 Novartis Ag Compuestos peptidicos, formulacion farmaceutica y sus usos como moduladores del virus de la hepatitis c
US8476257B2 (en) 2007-12-19 2013-07-02 Boehringer Ingelheim International Gmbh Viral polymerase inhibitors
WO2009099596A2 (en) 2008-02-04 2009-08-13 Idenix Pharamaceuticals, Inc. Macrocyclic serine protease inhibitors
US8188137B2 (en) 2008-08-15 2012-05-29 Avila Therapeutics, Inc. HCV protease inhibitors and uses thereof
SG172848A1 (en) 2009-01-07 2011-08-29 Scynexis Inc Cyclosporine derivative for use in the treatment of hcv and hiv infection
US8102720B2 (en) * 2009-02-02 2012-01-24 Qualcomm Incorporated System and method of pulse generation
EP2403860B1 (en) 2009-03-04 2015-11-04 IDENIX Pharmaceuticals, Inc. Phosphothiophene and phosphothiazole as hcv polymerase inhibitors
EP2417134B1 (en) 2009-04-08 2017-05-17 Idenix Pharmaceuticals LLC. Macrocyclic serine protease inhibitors
US8512690B2 (en) * 2009-04-10 2013-08-20 Novartis Ag Derivatised proline containing peptide compounds as protease inhibitors
US20110182850A1 (en) * 2009-04-10 2011-07-28 Trixi Brandl Organic compounds and their uses
CA2763140A1 (en) 2009-05-29 2010-12-02 Schering Corporation Antiviral compounds composed of three linked aryl moieties to treat diseases such as hepatitis c
WO2011017389A1 (en) 2009-08-05 2011-02-10 Idenix Pharmaceuticals, Inc. Macrocyclic serine protease inhibitors useful against viral infections, particularly hcv
US20110117055A1 (en) 2009-11-19 2011-05-19 Macdonald James E Methods of Treating Hepatitis C Virus with Oxoacetamide Compounds
JP2013512246A (ja) 2009-11-25 2013-04-11 メルク・シャープ・アンド・ドーム・コーポレーション ウイルス疾患治療に有用な縮合型三環式化合物およびその誘導体
CN102822175A (zh) 2009-12-18 2012-12-12 埃迪尼克斯医药公司 5,5-稠合的亚芳基或亚杂芳基丙型肝炎病毒抑制剂
CA2785488A1 (en) 2009-12-22 2011-07-21 Merck Sharp & Dohme Corp. Fused tricyclic compounds and methods of use thereof for the treatment of viral diseases
MA34147B1 (fr) 2010-03-09 2013-04-03 Merck Sharp & Dohme Composes tricycliques fusionnes de silyle et leurs methodes d'utilisation dans le cadre du traitement de maladies virales
EP2598149A4 (en) 2010-07-26 2014-09-10 Merck Sharp & Dohme SUBSTITUTED BIPHENYLENE COMPOUNDS AND METHOD FOR USE THEREOF FOR THE TREATMENT OF VIRUS DISEASES
JP2013540122A (ja) 2010-09-29 2013-10-31 メルク・シャープ・エンド・ドーム・コーポレイション 縮合四環式化合物誘導体およびウィルス疾患治療のためのそれの使用方法
AR085352A1 (es) 2011-02-10 2013-09-25 Idenix Pharmaceuticals Inc Inhibidores macrociclicos de serina proteasa, sus composiciones farmaceuticas y su uso para tratar infecciones por hcv
US20120252721A1 (en) 2011-03-31 2012-10-04 Idenix Pharmaceuticals, Inc. Methods for treating drug-resistant hepatitis c virus infection with a 5,5-fused arylene or heteroarylene hepatitis c virus inhibitor
MX2013011944A (es) 2011-04-13 2014-05-07 Merck Sharp & Dohme Derivados de nucleosidos 2'-sustituidos y metodos de uso de los mismos para el tratamiento de enfermedades virales.
US9156872B2 (en) 2011-04-13 2015-10-13 Merck Sharp & Dohme Corp. 2′-azido substituted nucleoside derivatives and methods of use thereof for the treatment of viral diseases
WO2013033901A1 (en) 2011-09-08 2013-03-14 Merck Sharp & Dohme Corp. Heterocyclic-substituted benzofuran derivatives and methods of use thereof for the treatment of viral diseases
WO2013033899A1 (en) 2011-09-08 2013-03-14 Merck Sharp & Dohme Corp. Substituted benzofuran compounds and methods of use thereof for the treatment of viral diseases
WO2013033900A1 (en) 2011-09-08 2013-03-14 Merck Sharp & Dohme Corp. Tetracyclic heterocycle compounds and methods of use thereof for the treatment of viral diseases
EP2755981A4 (en) 2011-09-14 2015-03-25 Merck Sharp & Dohme HETEROCYCLIC COMPOUNDS CONTAINING SILYL AND METHODS OF USING THE SAME FOR TREATING VIRAL DISEASES
WO2015042375A1 (en) 2013-09-20 2015-03-26 Idenix Pharmaceuticals, Inc. Hepatitis c virus inhibitors
US10167298B2 (en) 2013-10-30 2019-01-01 Merck Sharp & Dohme Corp. Pseudopolymorphs of an HCV NS5A inhibitor and uses thereof
EP3114122A1 (en) 2014-03-05 2017-01-11 Idenix Pharmaceuticals LLC Solid forms of a flaviviridae virus inhibitor compound and salts thereof
WO2015134561A1 (en) 2014-03-05 2015-09-11 Idenix Pharmaceuticals, Inc. Pharmaceutical compositions comprising a 5,5-fused heteroarylene flaviviridae inhibitor and their use for treating or preventing flaviviridae infection
CN111788204B (zh) * 2018-02-26 2023-05-05 吉利德科学公司 作为hbv复制抑制剂的取代吡咯嗪化合物
WO2023133174A1 (en) * 2022-01-07 2023-07-13 Merck Sharp & Dohme Llc Protease inhibitors for treating or preventing coronavirus infection

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU220204B (hu) 1987-11-18 2001-11-28 Chiron Corp. HCV polipeptidek és HCV polinukleotidok, ilyen polinukleotidokat tartalmazó vektorok és ezekkel transzformált gazdasejtek, valamint HCV fertőzés kimutatására szolgáló diagnosztikumok és immunvizsgálati készlet
DE69024378T2 (de) 1989-02-01 1996-09-12 Asahi Glass Co Ltd Azeotrope oder azeotropähnliche Zusammensetzung auf der Basis von Chlorfluorkohlenwasserstoffen
EP0527788B1 (en) 1990-04-04 2004-06-30 Chiron Corporation Hepatitis c virus protease
US5922757A (en) 1996-09-30 1999-07-13 The Regents Of The University Of California Treatment and prevention of hepatic disorders
PL194025B1 (pl) 1996-10-18 2007-04-30 Vertex Pharma Inhibitory proteaz serynowych, a zwłaszcza proteazy wirusa NS3 zapalenia wątroby C, kompozycja farmaceutyczna i zastosowanie inhibitorów proteaz serynowych
GB9623908D0 (en) 1996-11-18 1997-01-08 Hoffmann La Roche Amino acid derivatives
ES2234144T3 (es) 1997-08-11 2005-06-16 Boehringer Ingelheim (Canada) Ltd. Analogos de peptidos inhibidores de la hepatitis c.
AR022061A1 (es) 1998-08-10 2002-09-04 Boehringer Ingelheim Ca Ltd Peptidos inhibidores de la hepatitis c, una composicion farmaceutica que los contiene, el uso de los mismos para preparar una composicion farmaceutica, el uso de un producto intermedio para la preparacion de estos peptidos y un procedimiento para la preparacion de un peptido analogo de los mismos.
US6323180B1 (en) 1998-08-10 2001-11-27 Boehringer Ingelheim (Canada) Ltd Hepatitis C inhibitor tri-peptides
US6608027B1 (en) 1999-04-06 2003-08-19 Boehringer Ingelheim (Canada) Ltd Macrocyclic peptides active against the hepatitis C virus
UA74546C2 (en) 1999-04-06 2006-01-16 Boehringer Ingelheim Ca Ltd Macrocyclic peptides having activity relative to hepatitis c virus, a pharmaceutical composition and use of the pharmaceutical composition
JP2001049593A (ja) 1999-07-22 2001-02-20 E I Du Pont De Nemours & Co 全芳香族合成繊維からなる繊維紙及びその製造方法及び積層板
ES2240446T3 (es) 2000-04-03 2005-10-16 Vertex Pharma Inhibidores de serina proteasas, particularmente la proteasa ns3 del virus de la hepatitis c.
DE60137207D1 (de) 2000-04-05 2009-02-12 Schering Corp Makrozyklische inhibitoren der ns3-serinprotease des hepatitis c-virus mit stickstoffhaltigen zyklischen p2-gruppen
SK14952002A3 (sk) 2000-04-19 2003-03-04 Schering Corporation Makrocyklické zlúčeniny, farmaceutický prostriedok s ich obsahom a ich použitie
US7244721B2 (en) * 2000-07-21 2007-07-17 Schering Corporation Peptides as NS3-serine protease inhibitors of hepatitis C virus
WO2002008251A2 (en) 2000-07-21 2002-01-31 Corvas International, Inc. Peptides as ns3-serine protease inhibitors of hepatitis c virus
BR0112666A (pt) 2000-07-21 2003-06-10 Schering Corp Peptìdeos como inibidores de ns3-serina protease de vìrus da hepatite c
PL206255B1 (pl) * 2000-07-21 2010-07-30 Dendreon Corporationdendreon Corporation Inhibitor proteazy wirusa zapalenia wątroby C, zawierająca go kompozycja farmaceutyczna i zastosowanie inhibitora do wytwarzania leku do leczenia chorób związanych z HCV oraz zastosowanie do wytwarzania kompozycji do stosowania w kombinowanej terapii
AR029851A1 (es) 2000-07-21 2003-07-16 Dendreon Corp Nuevos peptidos como inhibidores de ns3-serina proteasa del virus de hepatitis c
AR034127A1 (es) 2000-07-21 2004-02-04 Schering Corp Imidazolidinonas como inhibidores de ns3-serina proteasa del virus de hepatitis c, composicion farmaceutica, un metodo para su preparacion, y el uso de las mismas para la manufactura de un medicamento
US6911428B2 (en) * 2000-12-12 2005-06-28 Schering Corporation Diaryl peptides as NS3-serine protease inhibitors of hepatitis C virus
US7241796B2 (en) * 2001-10-24 2007-07-10 Vertex Pharmaceuticals Inc. Inhibitors of serine proteases, particularly HCV NS3-NS4A protease
CA2473070C (en) 2002-01-23 2009-10-13 Schering Corporation Proline compounds as ns3-serine protease inhibitors for use in treatment of hepatites c virus infection
JP4874227B2 (ja) * 2004-02-27 2012-02-15 シェーリング コーポレイション Ｃ型肝炎ウイルスのｎｓ３セリンプロテアーゼインヒビターとしての環状ｐ４’ｓを有する新規ケトアミド
WO2005087730A1 (en) * 2004-02-27 2005-09-22 Schering Corporation 3,4-(cyclopentyl)-fused proline compounds as inhibitors of hepatitis c virus ns3 serine protease

Also Published As

Publication number Publication date
TW200602037A (en) 2006-01-16
WO2005087721A2 (en) 2005-09-22
RU2006134005A (ru) 2008-04-10
US7192957B2 (en) 2007-03-20
EP1748983A2 (en) 2007-02-07
IL177545A0 (en) 2006-12-10
US7718691B2 (en) 2010-05-18
AR047902A1 (es) 2006-03-01
CN1946691A (zh) 2007-04-11
CA2557247A1 (en) 2005-09-22
WO2005087721A3 (en) 2005-11-10
US20050288233A1 (en) 2005-12-29
US7759499B2 (en) 2010-07-20
US20070032434A1 (en) 2007-02-08
KR20060127162A (ko) 2006-12-11
BRPI0508095A (pt) 2007-07-17
US20070049536A1 (en) 2007-03-01
JP2007525510A (ja) 2007-09-06
NO20064356L (no) 2006-11-24
ECSP066795A (es) 2006-11-16
AU2005222055A1 (en) 2005-09-22

Similar Documents

Publication Publication Date Title
IL177545A0 (en) Compounds as inhibitors of hepatitis c virus ns3 serine protease
ZA200607053B (en) Novel compounds as inhibitors of hepatitis C virus NS3 serine protease
ZA200607096B (en) Sulfur compounds as inhibitors of hepatitis C virus NS3 serine protease
HK1099028A1 (en) Substituted prolines as inhibitors of hepatitis c virus ns3 serine protease
ZA200607134B (en) Inhibitors of hepatitis C virus NS3 protease
IL176237A0 (en) Inhibitors of hepatitis c virus ns3/ns4a serine protease
IL174459A0 (en) Macrocyclic inhibitors of hepatitis c virus ns3 serine protease
HK1095820A1 (en) 3,4-(cyclopentyl)-fused proline compounds as inhibitors of hepatitis c virus ns3 serine protease
IL201427A0 (en) Sulfur compounds as inhibitors of hepatitis c virus ns3 serine protease
IL177628A0 (en) Novel ketoamides with cyclic p4s as inhibitors of ns3 serine protease of hepatitis c virus
TWI367211B (en) Hcv ns-3 serine protease inhibitors
IL195512A0 (en) Quinoxalinyl macrocyclic hepatitis c virus serine protease inhibitors
IL162815A0 (en) Novel peptides as ns3-serine protease inhibitors of hepatitis c virus
AU2009225346B2 (en) Sulfur compounds as inhibitors of Hepatitis C virus NS3 serine protease